| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.38B | 22.36B | 21.68B | 21.71B | 18.00B | 14.46B |
| Gross Profit | 9.06B | 8.47B | 7.71B | 8.14B | 6.95B | 5.58B |
| EBITDA | 4.68B | 4.22B | 3.78B | 4.26B | 3.52B | 2.84B |
| Net Income | 2.17B | 1.94B | 1.51B | 2.04B | 1.73B | 1.41B |
Balance Sheet | ||||||
| Total Assets | 44.60B | 46.05B | 46.68B | 49.06B | 41.93B | 25.09B |
| Cash, Cash Equivalents and Short-Term Investments | 2.37B | 2.68B | 1.64B | 1.44B | 1.32B | 656.00M |
| Total Debt | 15.70B | 16.21B | 16.65B | 16.65B | 14.31B | 5.50B |
| Total Liabilities | 26.88B | 27.81B | 28.55B | 29.20B | 25.87B | 12.58B |
| Stockholders Equity | 17.68B | 18.20B | 18.08B | 19.84B | 16.04B | 12.50B |
Cash Flow | ||||||
| Free Cash Flow | 2.62B | 1.77B | 971.00M | 1.40B | 2.11B | 1.25B |
| Operating Cash Flow | 3.39B | 2.47B | 1.81B | 2.26B | 2.78B | 1.80B |
| Investing Cash Flow | -965.00M | -666.00M | -1.07B | -868.00M | -14.14B | -1.91B |
| Financing Cash Flow | -1.99B | -1.30B | -380.00M | -1.40B | 11.99B | -126.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $55.26B | 25.58 | 11.75% | 1.92% | 5.85% | 16.20% | |
| ― | €13.68B | 21.05 | 4.83% | 3.06% | 0.53% | 23.79% | |
| ― | €15.08B | 100.80 | 5.01% | 0.37% | 5.82% | 59.90% | |
| ― | €27.32B | 24.53 | 7.30% | 2.04% | -0.59% | ― | |
| ― | €50.02B | 17.47 | 10.08% | 1.92% | 1.67% | 9.02% | |
| ― | €4.10B | 25.89 | 7.48% | 1.31% | 5.21% | -39.36% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Siemens Healthineers’ recent earnings call painted a picture of robust performance, with the company achieving notable growth across key segments. The sentiment was largely positive, driven by successful initiatives such as Value Partnerships and a transformative approach in Diagnostics. However, challenges such as tariff and foreign exchange headwinds, coupled with difficulties in the Chinese market, were highlighted as potential concerns for upcoming quarters.
Siemens Healthineers is a leading global medical technology company specializing in imaging, diagnostics, and advanced therapies, with a focus on healthcare innovations that improve patient outcomes worldwide.